CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is Australia's number one index weight. Formerly the Commonwealth Serum Laboratory it became a listed entity in June 1994.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$294.43

28 Oct
2020

2.460

OPEN

$292.20

0.84%

HIGH

$296.49

0

LOW

$292.20

TARGET
$309.957 5.3% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . AVH . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . OPT .
MARKET CONSENSUS FORECAST
CSL: 1
Title FY21
Forecast		 FY22
Forecast
EPS (cps) 727.4 xxx
DPS (cps) 319.5 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 40.1 xxx
Dividend Yield 1.1% xxx
Div Pay Ratio(%) 43.9% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.45%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.69

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 10/09 - 148.1c (0%)

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

23/10/2020

3

Hold

$290.00

-1.50%

Ord Minnett believes the rise in covid-19 infections in the US over the last few weeks raises the risk of plasma collections recovery slowing down or reversing.

The broker reviews the locations of CSL's collection centres, comparing it to the covid-19 hot spots in the US. According to the broker, nearly 75% of CSL centres are in the "Red Zone" states (with more than 100 confirmed infections per 100,000 people).

CSL's competitors are in the same boat with 83% of Takeda's centres and 76% of Grifols' centres in these states.

Hold rating and $290 target retained.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

FORECAST
Ord Minnett forecasts a full year FY21 dividend of 322.72 cents and EPS of 731.41 cents.
Ord Minnett forecasts a full year FY22 dividend of 352.06 cents and EPS of 793.02 cents.

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CSL STOCK CHART

FNArena News on CSL

1
Equities Portfolio For 2021

10:01 AM - Rudi's View
2
US Election & Pandemic Investments – Part I

Oct 26 2020 - Australia
3
Rudi’s View: Quality & Growth, Confidence & Execution

Oct 22 2020 - Rudi's View
4
FNArena Book Review: Good To Great

Oct 20 2020 - Book Reviews
5
Biotech In Focus In 2020

Oct 16 2020 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Biotech In Focus In 2020

Oct 16 2020 - Australia
2
Does CSL’s Share Price Reflect All Risks?

Oct 12 2020 - Australia
3
Spotlight On CSL Revenue Targets

Sep 14 2020 - Australia
4
Opportunity in CSL

Sep 08 2020 - Technicals
5
Race Oncology Booming Ahead In Times Of Covid

Aug 28 2020 - Small Caps
6
ASX Biotechs Surfing The Covid Story

Aug 10 2020 - Weekly Reports
7
Tight Plasma Supply A Benefit For CSL Pricing

Jun 18 2020 - Australia
8
Hygiene Becomes The New Normal

Jun 01 2020 - Weekly Reports
9
Hand Sanitisers: Clean Up Or Clean Out?

Apr 22 2020 - Weekly Reports
10
CSL Plasma Collections Likely To Remain Robust

Mar 24 2020 - Australia